2/11
04:05 pm
pcvx
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
Low
Report
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
2/10
04:23 pm
pcvx
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026 [Yahoo! Finance]
Low
Report
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026 [Yahoo! Finance]
2/10
04:05 pm
pcvx
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
Low
Report
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
2/5
04:05 pm
pcvx
Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit
Medium
Report
Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit
2/2
08:36 pm
pcvx
Vaxcyte Funding And Late-Stage Trials Put Valuation In Focus [Yahoo! Finance]
Low
Report
Vaxcyte Funding And Late-Stage Trials Put Valuation In Focus [Yahoo! Finance]
2/2
04:44 pm
pcvx
Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares [Yahoo! Finance]
Low
Report
Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares [Yahoo! Finance]
2/2
04:05 pm
pcvx
Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Low
Report
Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
2/2
10:01 am
pcvx
Vaxcyte (NASDAQ:PCVX) had its "buy" rating reaffirmed by analysts at Guggenheim. They now have a $116.00 price target on the stock.
Medium
Report
Vaxcyte (NASDAQ:PCVX) had its "buy" rating reaffirmed by analysts at Guggenheim. They now have a $116.00 price target on the stock.
1/30
07:12 pm
pcvx
Vaxcyte Announces Pricing of $550 Million Public Offering [Yahoo! Finance]
Medium
Report
Vaxcyte Announces Pricing of $550 Million Public Offering [Yahoo! Finance]
1/29
11:33 pm
pcvx
Vaxcyte Announces Pricing of $550 Million Public Offering
Low
Report
Vaxcyte Announces Pricing of $550 Million Public Offering
1/29
07:04 pm
pcvx
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]
Low
Report
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]
1/29
04:06 pm
pcvx
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
Medium
Report
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
1/26
03:29 am
pcvx
Evercore ISI Rates Vaxcyte Inc. (PCVX) as an Overweight Following CDC Changes to Childhood Vaccination Recommendations [Yahoo! Finance]
Low
Report
Evercore ISI Rates Vaxcyte Inc. (PCVX) as an Overweight Following CDC Changes to Childhood Vaccination Recommendations [Yahoo! Finance]
1/24
07:11 pm
pcvx
Vaxcyte (PCVX) Is Up 13.2% After Expanding Late-Stage VAX-31 Program And Manufacturing Plans [Yahoo! Finance]
Low
Report
Vaxcyte (PCVX) Is Up 13.2% After Expanding Late-Stage VAX-31 Program And Manufacturing Plans [Yahoo! Finance]
1/22
05:12 pm
pcvx
Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine [Yahoo! Finance]
Medium
Report
Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine [Yahoo! Finance]
1/22
05:00 pm
pcvx
Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine
Low
Report
Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine
1/13
04:06 am
pcvx
Vaxcyte (NASDAQ:PCVX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Vaxcyte (NASDAQ:PCVX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/7
07:08 am
pcvx
Vaxcyte (NASDAQ:PCVX) had its "buy" rating reaffirmed by analysts at Needham & Company LLC.
Low
Report
Vaxcyte (NASDAQ:PCVX) had its "buy" rating reaffirmed by analysts at Needham & Company LLC.
1/3
10:46 am
pcvx
Vaxcyte's Chief Technical Ops Officer Sells Shares [Yahoo! Finance]
Low
Report
Vaxcyte's Chief Technical Ops Officer Sells Shares [Yahoo! Finance]
12/23
03:34 pm
pcvx
What Makes Vaxcyte (PCVX) So Attractive [Yahoo! Finance]
Low
Report
What Makes Vaxcyte (PCVX) So Attractive [Yahoo! Finance]
12/14
03:11 pm
pcvx
How Vaxcyte's Phase 3 Head-to-Head VAX-31 Trial Could Shape Vaxcyte (PCVX) Investors [Yahoo! Finance]
Low
Report
How Vaxcyte's Phase 3 Head-to-Head VAX-31 Trial Could Shape Vaxcyte (PCVX) Investors [Yahoo! Finance]
12/14
02:43 pm
pcvx
Vaxcyte (PCVX): Assessing a Discounted Valuation After a Volatile Year in the Share Price [Yahoo! Finance]
Low
Report
Vaxcyte (PCVX): Assessing a Discounted Valuation After a Volatile Year in the Share Price [Yahoo! Finance]
12/11
11:30 am
pcvx
Vaxcyte, Inc. (PCVX) Makes Strides on Pneumonia Treatment, Plots Coverage Extension [Yahoo! Finance]
Low
Report
Vaxcyte, Inc. (PCVX) Makes Strides on Pneumonia Treatment, Plots Coverage Extension [Yahoo! Finance]
12/8
07:00 am
pcvx
Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
Low
Report
Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
11/21
07:53 am
pcvx
Vaxcyte (PCVX): Evaluating Valuation After a 48% Three-Month Share Price Rebound [Yahoo! Finance]
Low
Report
Vaxcyte (PCVX): Evaluating Valuation After a 48% Three-Month Share Price Rebound [Yahoo! Finance]